Relmada Therapeutics's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; Relmada Therapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is €-0.80. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ -96.40K	-	$ 96.40K	-	$ 0.00
Gross Profit	$ 83.60K	-	$ 276.40K	$ -29.58M	-
EBIT	$ -26.42M	$ -23.32M	$ 29.99M	$ -45.41M	$ -38.74M
EBITDA	$ -26.42M	$ -23.32M	$ 29.99M	$ -45.41M	$ -38.74M
Net Income Common Stockholders	$ -25.17M	$ -22.00M	$ 29.99M	$ -37.94M	$ -39.42M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 96.32M	$ 106.27M	$ 132.44M	$ 148.32M	$ 184.15M
Total Assets	$ 97.55M	$ 109.15M	$ 135.57M	$ 152.91M	$ 187.12M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Net Debt	$ -96.32M	$ -106.27M	$ -132.44M	$ -148.32M	$ -184.15M
Total Liabilities	$ 12.19M	$ 8.42M	$ 10.10M	$ 12.47M	$ 20.78M
Stockholders Equity	$ 85.36M	$ 100.73M	$ 125.47M	$ 140.44M	$ 166.34M
Cash Flow	-
Free Cash Flow	$ -10.25M	$ -11.63M	$ -16.51M	$ -35.88M	$ -26.86M
Operating Cash Flow	$ -10.25M	$ -11.63M	$ -16.51M	$ -35.88M	$ -26.86M
Investing Cash Flow	$ 7.74M	$ 3.86M	$ 40.00M	$ -1.66M	$ 31.56M
Financing Cash Flow	$ -98.46K	-	-	$ 409.88K	$ 569.09K

Currency in USD

Relmada Therapeutics Earnings and Revenue History

Income Statement >

Relmada Therapeutics Debt to Assets

Balance Sheet >

Relmada Therapeutics Cash Flow

Cash Flow >

Relmada Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing